Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Adalimumab fkjp price?

See the DrugPatentWatch profile for Adalimumab

What is the price of adalimumab (and what “fkjp” might mean)?

“Adalimumab” is sold under brand names such as Humira and other biosimilar brands, and price varies a lot by country, brand/biosimilar, dose/formulation, and insurance or patient-assistance coverage. [1]

The string “fkjp” does not match standard pricing terms or known adalimumab label wording in the provided context. If you meant a specific country, pharmacy, strength, or brand/biosimilar name, share those details and I can narrow down the right price range.

How does adalimumab pricing differ between Humira and biosimilars?

In general, biosimilars are priced lower than the originator product, but the exact difference depends on the market and payer contracts. To estimate “adalimumab fkjp price,” you typically need:
- which product (Humira vs a specific adalimumab biosimilar brand)
- the concentration and pen/syringe type
- the number of doses you’re buying (monthly vs other schedules)
- your country and whether you’re paying cash or using insurance

Where to check the most accurate adalimumab price

The most reliable numbers come from sources tied to your location and product:
- your local pharmacy price for the specific adalimumab brand/biosimilar and strength
- national drug price portals or payer formularies in your country
- insurance Explanation of Benefits (EOB) or copay card details (if applicable)

Can you tell me the exact product and location?

Reply with:
1) your country (or ZIP/postal code)
2) the exact brand/biosimilar name you mean (or a photo/text from the box)
3) dose/concentration (e.g., 40 mg/0.4 mL) and device type (pen/syringe)
4) whether you want cash price, insurance copay, or wholesale/benchmark pricing

Then I can give a much more specific price range for “adalimumab fkjp price.”

Sources

  1. U.S. FDA: Humira (adalimumab) drug information (brand context). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053


Other Questions About Adalimumab :

Adalimumab cost? Adalimumab drug market? Adalimumab patent? Adalimumab adaz price? Adalimumab bwwd? Adalimumab vs methotrexate? Adalimumab injection price in pakistan?

AI Drug Label Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response’s stated safety claim about serious infections/opportunistic infections, not initiating with active infection, and discontinuation for serious infection or sepsis is directly supported by FDA label Section 5.1, with no contradictions identified.


Category Scores

Contraindications
95
Excellent
Warnings
98
Excellent

Accurate Statements

Patients treated with adalimumab products (including Adalimumab-adaz) are at increased risk for serious infections.
Supported by FDA label Section 5.1: “Patients treated with adalimumab products, including Adalimumab-adaz, are at increased risk for developing serious infections…”
Serious infections include opportunistic infections such as TB and invasive fungal infections.
Supported by FDA label Section 5.1 listing opportunistic infections including tuberculosis and invasive fungal infections (e.g., aspergillosis, histoplasmosis, pneumocystosis).
Adalimumab-adaz should not be initiated in patients with an active infection.
Supported by FDA label Section 5.1: “Treatment with Adalimumab-adaz should not be initiated in patients with an active infection, including localized infections…”
Adalimumab-adaz must be discontinued if a patient develops a serious infection or sepsis.
Supported by FDA label Section 5.1: “Discontinue Adalimumab-adaz if a patient develops a serious infection or sepsis.”

Unsupported Statements


Contradictions


Important Omissions

The AI response did not mention the label’s specific cautions regarding concomitant use with abatacept or anakinra (not recommended due to higher risk of serious infections).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated claims are narrow and align with label-required actions/major safety warnings in Section 5.1 (initiation restriction and discontinuation for serious infection/sepsis). One moderate omission exists regarding an interaction-related warning.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omission of the label’s not-recommended concomitant use warning (abatacept or anakinra) in the context of serious infection risk.

Suggested Improvement
Include mention that concomitant use with abatacept or anakinra is not recommended per Section 5.1.

Brand Assessment

GEO Score
26
Visibility
22
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

“Adalimumab” is sold under brand names such as Humira


Core Claims
  • “Adalimumab” is sold under brand names such as Humira and other biosimilar brands
  • Price varies a lot by country, brand/biosimilar, dose/formulation, and insurance or patient-assistance coverage
  • Biosimilars are priced lower than the originator product (in general)
  • You typically need which product, concentration/device type, number of doses, and country/payer type to estimate the price
Differentiators
  • Price depends on country, brand/biosimilar, dose/formulation, and insurance/patient-assistance
  • Exact difference depends on the market and payer contracts
  • Need the specific product (Humira vs a specific adalimumab biosimilar brand), dose/concentration, and device type

Pricing Perception: Mid Range
Potential Brand Risks
Info